Actavis UK accused of 12,000% hydrocortisone price hike

A government watchdog has alleged that Actavis UK has broken competition law by "excessively" overcharging the NHS for hydrocortisone tablets.

actavis_logo_620x413px.jpg
Speaking on behalf of Actavis UK, parent company Teva said it intends to defend the allegations

In its provisional findings of an investigation into the “excessive and unfair” pricing, the Competition and Markets Authority (CMA) found the UK pharmaceutical company increased the price of packs of 10mg hydrocortisone tablets by over 12,000% in eight years.

Free to registered users

Register to gain full access to C+D and C+D Community content

Sign in or register for free

Latest from News

Retired pharmacist crushed to death in canal boat accident

 
• By 
 • comment

Margaret Billings sustained fatal injuries when she was caught between a moving boat and a riverbank during a day out “with family and friends”, an inquest has found.

NHSE scrapped: ‘Fresh start or just more political chaos?’

 
• By 
 • comment

C+D rounds up some of the immediate pharmacy reaction to news that NHS England will be abolished, with more control moving back to the government and local leaders…

New primary care medical director role as 2-year NHSE axing begins

 
• By 
 • comment

Wes Streeting has revealed that the DH is “immediately” working to scrap NHS England (NHSE) and put a new “transformation team” in place – adding that it is in the “very final stages” of concluding a new pharmacy contract deal.

More from Business

breaking news

IN FULL: Boots’ parent company sold in $24bn private equity deal

 
• By 
 • comment

Walgreens Boots Alliance (WBA) has “entered into a definitive agreement to be acquired” by private equity firm Sycamore Partners.

Jhoots accounts: Shareholder funds tumble while debts soar

 
• By 
 • comment

Jhoots Chemist’s accounts for 2024 have revealed an almost £2 million year-on-year dip in shareholder funds – as debts to creditors increase more than £2m.